NPS leaps on upbeat US FDA Gattex review ahead of panel
This article was originally published in Scrip
NPS Pharmaceuticals' investigational short bowel syndrome (SBS) medicine Gattex (teduglutide) has had its share of ups and downs, but 12 October was a day investors viewed as optimistic, driving shares of the New Jersey firm up nearly 23% after the US FDA said it did not believe the drug should be restricted despite concerns about the risks of colon polyp and tumor growth, gastrointestinal obstruction and biliary and pancreatic disorders – outcomes that were observed in the experimental medication's development program.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.